5.2. imaging staging mibc. clinical practice, tumour stage histopathological grade used guide treatment determine prognosis [111-113]. imaging essential local- distant staging bc. goal imaging patients bc to: detect bladder tumours;differentiate t1 t2 tumours treatment differ;determine presence obstruction upper ut;evaluate extent locally-advanced tumour stage tumour spread lns;assess synchronous tumour upper ut distant organs (e.g., liver, lungs, bones, peritoneum, pleura, adrenal glands). table 5.1: role imaging treatment planning goalimaging modalitydifferentiate t1 t2 tumoursmri using vesical imaging reporting data system [vi-rads] scoreevaluate locally-advanced stage spread lnsct scan mri abdominal- pelvic lns pet/ct scanassess uut distant organsct urography evaluating uut pet/ct detect distant organ metastasis 5.2.1. detection imaging modalities used detect bladder tumours are: us, ct mri-scan. bladder tumours often detected part haematuria work-up (including cystoscopy) incidental finding imaging. ultrasound visualise intraluminal masses bladder additional signs hydronephrosis, cannot rule possible causes haematuria. according results detect trial, ct urogram safely replaced renal bladder us patients non-visible haematuria . 5.2.2. local staging bladder upper tract 5.2.2.1. magnetic resonance imaging local staging mibc differentiation nmibc mibc crucial bc treatment. magnetic resonance imaging superior soft tissue contrast resolution compared ct evaluate post-biopsy reaction enhancement tumour occurs earlier normal bladder wall due neovascularisation . accuracy mri primary tumour staging ranges 73% 96% (mean 85%). huang et al., systematic review, showed pooled sensitivity specificity 90% 88%, respectively, results increasing 92% 96% 3t scan used, diffusion-weighted (dw) mri part acquisition protocol . systematic review evaluating 20 studies (n = 1,724), showed pooled sensitivity specificity mri differentiating stages ≤ t1 ≥ t2 0.92 (95% ci: 0.88–0.95) 0.88 (95% ci: 0.78–0.94), respectively . recently, multiparametric (mp) mri using vi-rads scoring system introduced differentiate t1 vs. t2 bladder tumours high diagnostic accuracy . vi-rads offers standardised approach acquisition reporting mpmri bc; however, best practice using mpmri setting exact cut-off levels vi-rads scoring still need determined . date, vi-rads score validated several research groups, showing good diagnostic performance detecting mibc . also, high diagnostic performance detection muscle invasion urothelial carcinoma subtypes found . vi-rads assessment scoring proved independent predictor muscle-invasiveness, might facilitate shift toward aggressive approach selection patients high risk mibc, according novel proposed predictive pathway . meta-analysis found pooled sensitivity specificity mpmri vi-rads acquisition scoring predicting mibc 83% 90%, respectively . diagnostic performance using vi-rads scoring similar diagnostic performance conventional bladder mri determining mibc based previous meta-analysis 24 studies . analysis found substantial inter-reader agreement, kappa (κ) values ranging 0.81 0.92 . systematic review meta-analysis (n = 1,016) showed pooled weighted mean κ estimate 0.83 (95% ci: 0.78–0.88) . potential role mpmri first-line test local staging bc rather turb demonstrated recent clinical trial . modified delphi methodology recently developed panel highly experienced, internationally recognised radiologists, urologists, oncologists, radiation oncologists representative patient advocacy group, provide consensus-based recommendations urinary bladder mri help formulate international guidelines, particularly pre-operative cancer staging assessment response systemic therapy. among several statements reached agreement, experts recommend acquiring interpreting mr images according vi-rads recommendations always perform mri turbt, available . considering link established use gadolinium-based contrast agents nephrogenic systemic fibrosis (nsf) patients impaired renal function, contrast medium managed according european society urogenital radiology (esur) guidelines . interest growing role non-contrast mri assessment mibc using vi-rads studies demonstrating non-contrast-enhanced vi-rads scoring achieved similar predictive accuracy diagnosis mibc conventional vi-rads; however, additional evidence needed provide recommendation use non-contrast mri bladder cancer staging . 5.2.2.2. ct imaging local staging mibc general advantages ct imaging include high spatial resolution, shorter acquisition time, wider coverage single breath hold, lower susceptibility variable patient factors. computed tomography unable differentiate stages ta t3a tumours, useful detecting invasion perivesical fat (t3b) adjacent organs. accuracy ct determining extravesical tumour extension increases advanced disease . ct mri may used assessment local invasion t3b disease, higher, unable accurately diagnose microscopic invasion perivesical fat (t2 vs. t3a) . contrast-enhanced ct using iodinated contrast media considered alternative mri mri contraindicated available . 5.2.2.3. computed tomography urography local staging upper tract local staging uut, ctu highest diagnostic accuracy available imaging techniques. sensitivity ctu utuc 0.67–1.0 specificity 0.93–0.99 . rapid acquisition thin sections allows high-resolution isotropic images viewed multiple planes assist diagnosis without loss resolution. epithelial ‘flat lesions’ without mass effect urothelial thickening generally visible ct. secondary sign hydronephrosis associated advanced disease poor oncological outcome . presence enlarged lns highly predictive metastases utuc . 5.2.2.4. magnetic resonance urography local staging upper tract magnetic resonance urography indicated patients cannot undergo ctu, usually radiation iodinated contrast media contraindicated . sensitivity mr-urography 0.75 contrast injection tumours < 2 cm . use mr-urography gadolinium-based contrast media limited patients severe renal impairment (< 30 ml/min creatinine clearance), due risk nsf. computed tomography urography generally preferred mr-urography diagnosing staging utuc. 5.2.3. distant staging lymph nodes sites 5.2.3.1. imaging lymph nodes mibc assessment ln metastases based size alone limited; ct mri unable identify metastases normal-sized minimally-enlarged nodes. sensitivity modalities detection ln metastases low (48–87%). specificity also low nodal enlargement may due benign disease. overall, ct mri show similar results detection ln metastases variety primary pelvic tumours [135-137]. pelvic nodes > 8 mm abdominal nodes > 10 mm maximum short-axis diameter, detected ct mri, regarded pathologically enlarged . recent paper including 1,104 patients, conventional cross-sectional imaging showed slight concordance (64.9%) cn pn stages (sensitivity: 30%; specificity: 84%) . artificial intelligence-assisted lymph node metastases diagnostic model (lnmdm) whole slide images (ct, mri pet/ct) developed applied cohort 1,012 patients bladder cancer radical cystectomy pelvic lymph node dissection auc accurate diagnosis lnmdm ranged 0.978 (95% ci 0.960–0.996) 0.998 (95% ci: 0.996–1.000) five validation sets . 18f-fluorodeoxy glucose-positron emission tomography (fdg-pet) combined ct increasingly used clinical practice exact role still needs evaluated . according systematic review meta-analysis including 785 patients, fdg-pet/ct showed low sensitivity high specificity detection metastatic lns patients newly diagnosed bc . however, studies evaluating fdg-pet/ct ln assessment reported higher sensitivity ct, comparable specificity . pet/ct provide additional information guide local treatment case presence pelvic nodes metastases . however, clinical trial assessing role pet/ct evaluating ln involvement patients receiving neoadjuvant pembrolizumab. performance pet/ct justify routine use cn0 mibc patients, proved useful optimising selection mibc patients suited neoadjuvant immunotherapy (io) strategies clinical trial setting . several studies demonstrated possible role radiomics detection pathological lymph nodes bladder cancer patients; however, level evidence remains low. 5.2.3.2. distant metastases prior curative treatment, essential evaluate presence distant metastases. computed tomography mri diagnostic techniques choice detect e.g., lung liver metastases , respectively. evidence role fdg-pet/ct staging distant metastases mibc still limited. recent series 711 patients, fdg-pet/ct shown provide important staging information detection distant metastases, may impact clinical management mibc patients . bone brain metastases rare time presentation invasive bc. recent retrospective, large sample, study bone scan shown impact patients’ intended management 19 1,148 (1.7%) patients, therefore routinely used . whole- body mri sensitive specific diagnosing bone metastases bone scintigraphy . also, additional brain imaging routinely indicated unless patient specific symptoms signs suggest brain metastases. 5.2.4. response therapy pre-operative mri conducted various clinical settings may provide useful information regarding treatment response. neoadjuvant setting, first study evaluating performance mri assessing therapeutic response chemotherapy showed superiority dwi t2-weighted dynamic contrast-enhanced (dce)-mri . high specificity dwi indicates usefulness accurate predicting complete histopathological response, allowing better patient selection bladder-sparing protocols . dynamic contrast-enhanced mr imaging may also useful predicting patient’s response chemotherapy. addition, quantitative dwi/mri analysis shown provide accurate non-invasive assessment bladder rt response. however, multicentre validation required prospective testing inform mibc follow-up schedules decision making . previously cited consensus-based recommendations, experts agreed upon performance mri assess response systemic therapy select patients radical treatment, surveillance, bladder-sparing surgery . meta-analysis investigated predictive role 18f-fdg pet/ct assessment tumour response neoadjuvant chemotherapy total 278 patients, showed pooled sensitivity 0.84 (95% ci, 0.72–0.91), specificity 0.75 (95% ci, 0.59–0.86). among five studies, three used cr pcr reference standard . performance pet/ct evaluating ln involvement patients receiving neoadjuvant pembrolizumab justify routine use cn0 mibc patients . 5.2.5. future perspectives potential future application vi-rads score may include prediction response treatment well peri-operative outcomes using modified version: nac vi-rads (nacvi-rads), however, prospective evidence warranted . future trends might include image analysis radiomic-based techniques predicting mibc. meta- analysis (n = 860) provided summary estimates sensitivity specificity predicting mibc 82% (95% ci: 77–86%) 81% (95% ci: 76–85%), respectively . pet/mri combining benefits mri functional imaging could evisioned detection metastatic bc lesions seen ct patients cannot receive intravenous iodine contrast, may lead improved treatment planning monitoring bc . among novel approaches radiotracers, pilot study, rietbergen et al., showed sentinel node (sn) biopsy bladder cancer using hybrid tracer icg- 99mtc-nanocolloid feasible, patients successful pre-operative sn mapping using lymphoscintigraphy spect/ct, intraoperative sn guidance detection effective, even outside extended pelvic lymph node dissection (eplnd) area . 5.2.6. summary evidence guidelines staging muscle-invasive bladder cancer summary evidenceleimaging part staging muscle-invasive bladder cancer (mibc) provides information prognosis assists selection appropriate treatment.2bthe diagnosis upper tract uc depends ct urography and, needed, ureteroscopy.2bin local staging, mri superior ct terms differentiating t1 t2 disease.2bmri accurate assessment tumour response systemic therapy3bone scintigraphy limited value staging invasive bc.3fdg-pet/ct provide additional information guide treatment.2b recommendationsstrength ratingalways perform mri turbt, available.weakin patients confirmed muscle-invasive bladder cancer, use computed tomography (ct) chest, abdomen pelvis staging, including form ct urography designated phases optimal urothelial evaluation.stronguse ct urography, unless contraindicated reasons related contrast adminstration radiation dose; case use magnetic resonance imaging.strongoffer mri assess response systemic therapy, aids selection patients radical treatment, surveillance, bladder-sparing surgery.weak